## HIV-1 glycoprotein gp120 upregulates activation of Pyk2 and Akt signaling pathways in mice glioma cells

Gabriel Valentín-Guillama, Lilia Kucheravykh Biochemistry Department, UCC-School of Medicine, Bayamon P.R.

cy virus type 1 (HIV-1) are more prone to (GBMs). The median survival for GBM in for HIV-negative GBM patients, even difference indicates that HIV infection is or and with treatment resistance. Earlier lein in the HIV shell, stimulates glycolysis

e underlying gp120-dependent signaling GL-261 were continuously cultured for 7 120 Bal III (100ng/ml) and collected for blot analysis presented an increase in ise (Pyk2(Y402)), p38(YT100/Y182) and yk2 pathway, along with the increased inase 3b (GSK3b (S9)) phosphorylation. ed an increase of G2/M phase in cells trol cells. Furthermore, GL-261 cells with ing showed no significant change in cell III.

commonly occurring malignant primary nts diagnosed with GBM is less than 5%, s demonstrated that expression of the vith shorter patient survival. CCL5 is an is CCR5<sup>3</sup>. The chemokine receptor CCR5 t also serves as a co-receptor for HIV

IV-1 glycoprotein gp120 upregulates in GBM tumors. Engagement of CCR5 r growth, induce extracellular matrix port cancer stem cell expansion, enable cytotoxicity of DNA-damaging agents, is. We hypothesize that gp120 interacts aling pathways that result in increased sis and upregulated glycolysis.


, Wolinsky, Y., ... & Barnholtz-Sloan, J. S. (2013). stem tumors diagnosed in the United States in


in the Treatment of Glioblastoma: Multisystem 16, 505–517.

eger, D., & Pestell, R. G. (2019). Recent Advances ancer research, 79(19), 4801–4807.

, N. E., Pérez, J., Ortiz-Rivera, J., Inyushin, M., kli, N., & Kucheryavykh, L. Y. (2018). HIV-1 Envelope colysis in Glioma Cell. Cancers, 10(9), 301.

L5/CCR5 Axis in Cancer Progression. Cancers, 12(7),








Figure 1: gp120 upregulates phorphorilation of Akt and GSK3β in GL-261 cells. Western blot and quantification of relative changes in phosphorilation of (A) pAkt (S473), (B) pGSK3β (S9) and (C) pPyk2 (Y402) for untreated and gp120-treated mice glioma cells. β-Actin 0r β-Tubulin were used as loading controls. Results are presented as mean  $\pm$  S.D. with significant difference from control (\*) (p≤0.05), (\*\*) (p≤0.005). An unpaired t-test was used to determine the significance between gp120-treated and untreated groups. Three independent experiments (n = 3) for each cell line were used for statistical analysis.




Figure 2: gp120 increases proliferation rate in Gl-261 but not in GL-261<sup>KO</sup>. Graphical representation of total amount of live cells after 7 day treatment with gp120  $(100 \text{ng/}\mu\text{L})$ . Change in total amount of cells represented in fold change compared to untreated cells. Results are presented as mean  $\pm$  S.D. with significant difference from control (\*\*) (p≤0.005). An unpaired t-test was used to determine the significance between gp120-treated and untreated groups. Four independent experiments (n = 4) for each cell line were used for statistical analysis.




Figure 3: gp120 upregulates cell cycle progression in GL-261 but not in GL-261<sup>100</sup> cells. Graphicytometry. The percentage of cells in the GO/G1, S and G2/M phases was determined based for untreated glioma cells and cells continuously treated with gp120 for 7 days. GL-261 a graphs represent the total distribution of cells at different phases of the cell cycle. The proposas a percentage of the total number of cells. Mean  $\pm$  S.D. and significant differences from cowere used to determine the significance between groups. Three repeated experiments (n = 3




Figure 4: gp120 activates MAPK pathways through Pyk2. Western blot (A) and phosphorilation of SAPK/JNK (T183/Y185), ERK (T202/204), P38 (T180/182) and, upr untreated and gp120 treated GL-261 and GL-261<sup>KO</sup>. β-Tubulin was used as loading contro significant difference from control (\*) (p≤0.05), (\*\*) (p≤0.005). An unpaired t-test was u gp120-treated and untreated groups. Three independent experiments (n = 3) for each ce

## Conclusions:

The HIV-1 glycoprotein gp120:

- •Increases proliferation in GI-261 but not in GL-261<sup>KO</sup>
- •Mediates cell cycle progression through Pyk2 activation
- •Leads to the phosphorilation of Akt (\$473), GSK3B (\$9) and Pvk2 (Y402)
- •Activates the P38 and ERK MAPK pathways along with upregulation of Cyclin D1 and phosph

## Acknowledgements

Images created with BioRender.com

Supported by:

• NIH Grant 1SC1GM122691

The following reagent was obtained through the NIH HIV Reagent Program, Division of AIDS, I Type 1 BaL gp120 Protein, Recombinant from HEK293 Cells, ARP-4961, contributed by DAIDS/